All In Biotech

NDA 209472 · Eagle Pharms

Pemfexy

Pemetrexed · Intravenous

Last checked: Nov 20, 2026Latest source record: Dec 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 8, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,475

328 Phase 3, 251 recruiting

FAERS reports

22,312

21,864 serious, 3,879 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 18, 2026.

PEMFEXY™ is a folate analog metabolic inhibitor indicated for: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use : PEMFEXY is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. ( 1.1 ) in combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) 1.1 Non-squamous Non-Small Cell Lung Cancer PEMFEXY ™ is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC...

Mechanism: Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers, such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 14, 2022 Supplement 5 · Efficacy LetterLabel
  • Feb 8, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • PEMFEXY · PEMETREXED 500MG/20ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pemetrexed" as an intervention, any sponsor and status, largest first.

All 1,475 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression1,726
  • anaemia1,313
  • disease progression1,147
  • off label use1,130
  • nausea1,071
  • neutropenia1,071
  • diarrhoea1,041
  • pancytopenia1,010
  • thrombocytopenia997
  • drug ineffective983
  • acute kidney injury840
  • vomiting823

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200436
200542
200617
200783
2008123
2009300
2010482
2011492
2012323
2013240
2014294
2015293
2016489
2017546
2018839
2019851
20201,050
20211,534
20222,220
20232,702
20243,452
20253,228
20262,676

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Pemfexy (Pemetrexed) · HCPCS J9304

2024 spending

$58.5M

Beneficiaries

2,819

11,881 claims

Per beneficiary

$20,745

2024 ASP limit $57.29 per unit

View as table
YearSpending
2020$0
2021$0
2022$18,389,656
2023$55,100,997
2024$58,480,776

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,004 on PubMed

Sponsor: Eagle Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.